Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 1, 2012, Pages 53-60

  Hughes, Lucinda ^a   Zhu, Fang ^a   Ross, Eric ^a   Gross, Laura ^a   Uzzo, Robert G ^a   Chen, David Y T ^a   Viterbo, Rosalia ^a   Rebbeck, Timothy R ^b   Giri, Veda N ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CHROMOSOME 10Q; CHROMOSOME 17Q; CHROMOSOME 19Q; CHROMOSOME 7Q; CHROMOSOME 8Q; COHORT ANALYSIS; CONTROLLED STUDY; EARLY ONSET PROSTATE CANCER; EUROPEAN AMERICAN; FAMILY HISTORY; FOLLOW UP; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AFRICAN AMERICANS; AGED; BIOPSY; COHORT STUDIES; EARLY DETECTION OF CANCER; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862974749     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0727     Document Type: Article

References (27)

1. Cancer facts and figures 2011. Atlanta: American Cancer Society: accessed July 26, 2011.
2. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993;150:797-802. (Pubitemid 23241269)
3. Catalona WJ, Antenor JA, Roehl KA, Moul JW. Screening for prostate cancer in high risk populations. J Urol 2002;168:1980-3; discussion 3-4.
4. Giri VN, Beebe-Dimmer J, Buyyounouski M, Konski A, Feigenberg SJ, Uzzo RG, et al. Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol 2007;178:1920-4; discussion 4.
5. Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer 2009;115:2863-71.
6. Kim ST, Cheng Y, Hsu FC, Jin T, Kader AK, Zheng SL, et al. Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic variation. Prostate 2010;70:1729-38.
7. Beebe-Dimmer JL, Levin AM, Ray AM, Zuhlke KA, Machiela MJ, Halstead-Nussloch BA, et al. Chromosome 8q24 markers: risk of early-onset and familial prostate cancer. Int J of Cancer 2008;122:2876-9. (Pubitemid 351631393)
8. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007;39:631-7. (Pubitemid 46676102)
9. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40:316-21. (Pubitemid 351311772)
10. Camp NJ, Farnham JM, Wong J, Christensen GB, Thomas A, Cannon-Albright LA. Replication of the 10q11 and Xp11 prostate cancer risk variants: results from a Utah pedigree-based study. Cancer Epidemiol Biomarkers Prev 2009;18:1290-4.
11. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006;38:652-8. (Pubitemid 43927306)
12. Yeager M, Chatterjee N, Ciampa J, Jacobs KB, Gonzalez-Bosquet J, Hayes RB, et al. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet 2009;41:1055-7.
13. Wang L, McDonnell SK, Slusser JP, Hebbring SJ, Cunningham JM, Jacobsen SJ, et al. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res 2007;67:2944-50. (Pubitemid 46724829)
14. Savage SA, Greene MH. The evidence for prostate cancer risk loci at 8q24 grows stronger. J Natl Cancer Inst 2007;99:1499-501. (Pubitemid 351767240)
15. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007;39:977-83. (Pubitemid 47185170)
16. Levin AM, Machiela MJ, Zuhlke KA, Ray AM, Cooney KA, Douglas JA. Chromosome 17q12 variants contribute to risk of early-onset prostate cancer. Cancer Res 2008;68:6492-5.
17. Douglas JA, Levin AM, Zuhlke KA, Ray AM, Johnson GR, Lange EM, et al. Common variation in the BRCA1 gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:1510-6. (Pubitemid 47076887)
18. Ross PL, Cheng I, Liu X, Cicek MS, Carroll PR, Casey G, et al. Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer. BMC Cancer 2009;9:69.
19. Douglas JA, Zuhlke KA, Beebe-Dimmer J, Levin AM, Gruber SB, Wood DP, et al. Identifying susceptibility genes for prostate cancer-a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev 2005;14:2035-9. (Pubitemid 41161220)
20. Eskew LA, Woodruff RD, Bare RL, McCullough DL. Prostate cancer diagnosed by the 5 region biopsy method is significant disease. J Urol 1998;160:794-6. (Pubitemid 29479516)
21. Rosser CJ, Broberg J, Case D, Eskew LA, McCullough D. Detection of high-grade prostatic intraepithelial neoplasia with the five-region biopsy technique. Urology 1999;54:853-6. (Pubitemid 29505585)
22. Blaesild P, Granfeldt J. Statistics with applications in biology and geology. First ed: Chapman and Hall/CRC; London 2002.
23. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995;57:289-300.
24. Newson R. Comparing the predictive power of survival models using Harrell's c or Somers' D. Stata J 2010;10:339-58.
25. Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, et al. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res 2009;69:5568-74.
26. Wasserman NF, Aneas I, Nobrega MA. An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. Genome Res 2010;20:1191-7.
27. Lange EM, Salinas CA, Zuhlke KA, Ray AM, Wang Y, Lu Y, et al. Early onset prostate cancer has a significant genetic component. The Prostate 2011. (epub ahead of print).